Organigram Global (NASDAQ:OGI) reported a dominant start to its fiscal 2026 on Tuesday, posting a 49% year-over-year surge in net revenue to $63.5 million.
The results, released February 10, 2026, mark the first quarterly report under new CEO James Yamanaka, who recently succeeded long-time chief Beena Goldenberg.
Yamanaka, who spent his first 25 days touring the company's Moncton and Lac-Supérieur facilities, emphasized a future focused on "efficiency and scale" as Organigram cements its position as Canada's top cannabis company by market share.
The company's bottom line saw even more dramatic improvement, with adjusted EBITDA skyrocketing 273% to $5.3 million.
This profitability was supported by a 43% increase in total kilograms harvested (28,645 kg), achieved through nutrient enhancements that lowered per-unit production costs.
Organigram maintained its #1 rank in the Canadian vape, milled flower, and concentrate categories, while its international revenue grew 51% to $5 million, fueled by exports to Israel, Australia, and Germany.
Beyond the financials, Organigram announced a proprietary genetic screening breakthrough that could revolutionize cultivation efficiency.